news contact north america canada united states latin america argentina brazil colombia mexico europe the middle east & africa alexion europe belgium denmark france germany ireland italy netherlands norway russia spain sweden switzerland turkey uae united kingdom asia pacific australia china india japan search for about alexion leadership our values responsibility citizenship corporate giving & support sustainability milestones awards & recognition partnerships patient focus ultra rare diseases patient stories access advocacy products soliris pnh ahus strensiq kanuma research and development pipeline our research eculizumab in other diseases other therapeutic candidates clinical trials investigator sponsored research sponsored research and collaborations careers job opportunities why choose alexion culture compensation and benefits professional development investors news contact switzerland vendor form select a country argentina australia belgium brazil china colombia denmark france germany india ireland italy japan mexico netherlands norway russia spain sweden switzerland turkey uae uk usa alexion launches uncommon strength campaign to unite and celebrate the courage and resilience of people living with rare diseases . learn more we see the unseen at alexion we see opportunities where others do not and we have the courage to explore what others believe is impossible . we see patients suffering from devastating diseases that are often overlooked . we see a pathway from innovative science to the delivery of breakthrough therapies . patient stories we see an opportunity to transform lives we have the passion to engineer our own course because the scientific challenges we choose to tackle require it . we are driven by our shared values to find answers change the world and create a legacy for patients and families in need . latest news view all news featured stories view all stories alexion employees volunteer in local communities at company s first global day of service alexion launches uncommon strength campaign to unite and celebrate the courage and resilience of people living with rare diseases alexion receives international investor award 2016 video meet adelyn a patient with hpp diagnosed at 2 days old find answers our entire global organization is focused on finding the most elusive answers for patients with devastating and rare diseases . we aim to achieve the impossible as we advance the most robust rare disease pipeline in the biotech industry with innovative product candidates across multiple therapeutic areas . research and development change the world by redefining innovation we have developed three breakthrough therapies to serve patients with four severe and ultra rare diseases . we deliver nothing less than transformation so that together with our patients we change the world . products create a legacy our commitment to transforming the lives of patients will be measured by the families we serve today and the generations that follow leaving no one behind . join us to create a lasting impact on patients and families around the world . careers alexion completes acquisition of synageva biopharma a message from david hallal ceo 2015 alexion legal privacy policy terms of use site map please see full prescribing information and important safety information for soliris eculizumab . this website is intended only for residents of the united states . about alexion leadership our values responsibility milestones awards & recognition partnerships patient focus ultra rare diseases patient stories access advocacy products soliris strensiq kanuma research and development pipeline our research clinical trials investigator sponsored research sponsored research and collaborations careers job opportunities why choose alexion investors news contact legal privacy policy terms of use site map 2016 alexion this website is intended only for residents of the united states . you are now leaving www.alexion.com a website provided by alexion pharmaceuticals inc. this link will take you to a different site to which this privacy policy does not apply . continuecancel